文献速递新发突发、热带与寄生虫病

氯喹、青蒿琥酯及氯喹联合伯氨喹治疗间日疟的累积疗效与安全性比较

Comparison of the Cumulative Efficacy and Safety of Chloroquine, Artesunate, and Chloroquine-Primaquine in Plasmodium vivax Malaria.
PubMed 文献 · Clin Infect Dis · 2018-01-01

在泰缅边境开展的三臂随机对照试验纳入644例无并发症间日疟患者,随访1年,比较青蒿琥酯、氯喹及氯喹联合伯氨喹的累积疗效与安全性。结果显示氯喹联合伯氨喹的复发率最低,伯氨喹根治可显著减少总体复发。

要点

  • 第28天复发率:青蒿琥酯50%(112/224),氯喹8%(18/222),氯喹联合伯氨喹0.5%(1/198)。
  • 伯氨喹根治使总体复发减少92.4%。
  • 第28天复发与血细胞比容平均绝对降低1%相关(95%CI 0.3%-2.0%;P=0.009)。

核心结论

  • 间日疟复发主要被氯喹延迟,但被伯氨喹预防。

研究设计与样本

  • 在泰缅边境开展的三臂随机对照试验,纳入644例无并发症间日疟患者,随访1年。

主要发现

  • 青蒿琥酯清除疟原虫血症显著快于氯喹。
  • 第28天复发率:青蒿琥酯50%(112/224),氯喹8%(18/222;P<0.001),氯喹联合伯氨喹0.5%(1/198;P<0.001)。
  • 首次复发中位时间:青蒿琥酯28天(IQR 21-42),氯喹49天(IQR 35-74),氯喹联合伯氨喹195天(IQR 82-281)。
  • 第28天复发与血细胞比容平均绝对降低1%相关(95%CI 0.3%-2.0%;P=0.009)。
  • 伯氨喹根治使总体复发减少92.4%。

关键数值与推荐

  • 青蒿琥酯方案:2 mg/kg/天,连用5天。
  • 氯喹方案:3天内总量25 mg基质/kg。
  • 氯喹联合伯氨喹方案:伯氨喹0.5 mg/kg/天,连用14天。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Chloroquine has been recommended for Plasmodium vivax infections for >60 years, but resistance is increasing. To guide future therapies, the cumulative benefits of using slowly eliminated (chloroquine) vs rapidly eliminated (artesunate) antimalarials, and the risks and benefits of adding radical cure (primaquine) were assessed in a 3-way randomized comparison conducted on the Thailand-Myanmar border. METHODS: Patients with uncomplicated P. vivax malaria were given artesunate (2 mg/kg/day for 5 days), chloroquine (25 mg base/kg over 3 days), or chloroquine-primaquine (0.5 mg/kg/day for 14 days) and were followed for 1 year. Recurrence rates and their effects on anemia were compared. RESULTS: Between May 2010 and October 2012, 644 patients were enrolled. Artesunate cleared parasitemia significantly faster than chloroquine. Day 28 recurrence rates were 50% with artesunate (112/224), 8% with chloroquine (18/222; P < .001), and 0.5% with chloroquine-primaquine (1/198; P < .001). Median times to first recurrence were 28 days (interquartile range [IQR], 21-42) with artesunate, 49 days (IQR, 35-74) with chloroquine, and 195 days (IQR, 82-281) with chloroquine-primaquine. Recurrence by day 28, was associated with a mean absolute reduction in hematocrit of 1% (95% confidence interval [CI], .3%-2.0%; P = .009). Primaquine radical cure reduced the total recurrences by 92.4%. One-year recurrence rates were 4.51 (95% CI, 4.19-4.85) per person-year with artesunate, 3.45 (95% CI, 3.18-3.75) with chloroquine (P = .002), and 0.26 (95% CI, .19-.36) with chloroquine-primaquine (P < .001). CONCLUSIONS: Vivax malaria relapses are predominantly delayed by chloroquine but prevented by primaquine. CLINICAL TRIALS REGISTRATION: NCT01074905.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Chu CS, Phyo AP, Lwin KM, et al. Comparison of the Cumulative Efficacy and Safety of Chloroquine, Artesunate, and Chloroquine-Primaquine in Plasmodium vivax Malaria. Clin Infect Dis. 2018. PMID: 29889239. doi:10.1093/cid/ciy319

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。